April 15, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Hemogenyx Pharmaceuticals on a series of clinical proteomics projects.
Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City and a Belgian subsidiary, Hemogenyx-Cell SPRL, located in Liège.
As a pre-clinical stage biopharmaceutical group, Hemogenyx is developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The Company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
